特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

組織工学(ティッシュエンジニアリング)の世界市場:市場規模・シェア・動向分析

Tissue Engineering Market Size, Share & Trends Analysis Report By Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Orthopedics, Musculoskeletal, & Spine), By Region, And Segment Forecasts, 2020 - 2027

発行 Grand View Research, Inc. 商品コード 639944
出版日 ページ情報 英文 140 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
組織工学(ティッシュエンジニアリング)の世界市場:市場規模・シェア・動向分析 Tissue Engineering Market Size, Share & Trends Analysis Report By Application (Cord Blood & Cell Banking, Cancer, GI & Gynecology, Dental, Orthopedics, Musculoskeletal, & Spine), By Region, And Segment Forecasts, 2020 - 2027
出版日: 2020年02月18日 ページ情報: 英文 140 Pages
概要

当レポートでは、世界の組織工学(ティッシュエンジニアリング)市場を調査し、市場の概要、用途・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、市場機会、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

第2章 エグゼクティブサマリー

  • 市場の見通し
  • 市場の見通し:セグメント別
  • 競合情勢
  • 市場スナップショット

第3章 市場変数・動向・範囲

  • 市場の見通し
  • 市場セグメンテーション
  • 市場力学
  • 普及率と成長見通し:用途別
  • PESTEL分析
  • ファイブフォース分析
  • 主な取引と戦略的提携の分析

第4章 世界の組織工学(ティッシュエンジニアリング)市場:用途別

  • 市場動向の分析:用途別
    • 臍帯血バンク・細胞バンク
    • 胃腸障害・婦人科
    • 歯科
    • 外皮・皮膚
    • 泌尿器
    • 整形外科・筋骨格・脊椎
    • 神経
    • 心血管
    • その他

第5章 世界の組織工学(ティッシュエンジニアリング)市場:地域別

  • 市場動向の分析:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第6章 競合情勢

  • 企業カテゴリー
  • 企業の市場ポジショニング
  • 主要企業
  • 戦略の枠組み
  • 企業プロファイル
    • Medtronic plc
    • Zimmer Biomet Holdings, Inc.
    • Allergan plc
    • Acelity L.P. Inc. (LifeCell)
    • ACell, Inc.
    • Athersys, Inc.
    • Organogenesis Holdings Inc.
    • Stryker Corporation
    • Tissue Regenix Group plc
    • RTI Surgical, Inc.
    • ReproCell, Inc.
    • Integra LifeSciences Corporation
    • Baxter International, Inc
図表

List of Tables

  • TABLE 1 FDA-approved regenerative medicines
  • TABLE 2 Approved engineered tissue products
  • TABLE 3 North America tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 5 Canada tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 6 Europe tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 7 U.K. tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 8 Germany tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 9 France tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 10 Asia Pacific tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 11 Japan tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 12 China tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 13 India tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 14 Latin America tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 15 Brazil tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 16 Mexico tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 17 MEA tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 18 South Africa tissue engineering market, by application, 2014 - 2025 (USD Million)
  • TABLE 19 List of tissue engineering companies

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain-based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market Snapshot, 2019, (USD Million)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Stem cell pipeline for cardiovascular and metabolic disorders, as of July 2018
  • FIG. 12 Future key trends in regenerative medicine
  • FIG. 13 Regenerative medicine stakeholders
  • FIG. 14 Therapeutic delivery methods investigated in preclinical research in 2017, U.K.
  • FIG. 15 Clinical trials for tissue engineering, by phase, EOY 2018
  • FIG. 16 Global financings of companies active in developing tissue engineering-based therapies for rare diseases
  • FIG. 17 Global regenerative medicine financings in oncology
  • FIG. 18 Market restraint relevance analysis (Current &future impact)
  • FIG. 19 Penetration & growth prospect mapping, by application, 2019
  • FIG. 20 Tissue engineering market - PESTEL analysis
  • FIG. 21 Porter's five forces analysis
  • FIG. 22 Tissue engineering market application outlook key takeaways
  • FIG. 23 Tissue engineering market: Application movement analysis
  • FIG. 24 Global cord blood & cell banking market, 2016 - 2027 (USD Million)
  • FIG. 25 Global cancer market, 2016 - 2027 (USD Million)
  • FIG. 26 Global GI & gynecology market, 2016 - 2027 (USD Million)
  • FIG. 27 Global dental market, 2016 - 2027 (USD Million)
  • FIG. 28 Global skin & integumentary market, 2016 - 2027 (USD Million)
  • FIG. 29 Global urology market, 2016 - 2027 (USD Million)
  • FIG. 30 Global orthopedics, musculoskeletal, & spine market, 2016 - 2027 (USD Million)
  • FIG. 31 Global neurology market, 2016 - 2027 (USD Million)
  • FIG. 32 Global cardiology & vascular market, 2016 - 2027 (USD Million)
  • FIG. 33 Global tissue engineering market for other applications, 2016 - 2027 (USD Million)
  • FIG. 34 Regional market place: Key takeaways
  • FIG. 35 Regional outlook, 2019 & 2027
  • FIG. 36 North America tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 37 U.S. tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 38 Canada tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 39 Europe tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 40 U.K. tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 41 Germany tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 42 France tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 43 Asia Pacific tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 44 Japan tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 45 China tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 46 India tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 47 Latin America tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 48 Brazil tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 49 Mexico tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 50 MEA tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 51 South Africa tissue engineering market, 2016 - 2027 (USD Million)
  • FIG. 52 Tissue engineering market: Company categorization
  • FIG. 53 Tissue engineering: Heat map analysis
  • FIG. 54 Strategy framework
目次
Product Code: 978-1-68038-768-1

The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and limitations regarding the implementation and availability of autologous transplants. Moreover, the development of specialized procedures including implant fixing and sterilization to transform allogeneic implants so for application as biostatic implants is expected to drive revenue generation in this market.

Rapid advancements and a strong pipeline of regenerative medicine are anticipated to provide effective solutions for chronic conditions. Several companies in growing markets are striving to capitalize on the untapped market potential with a strong focus on R&D. For instance, RepliCel is investing in multiple regenerative medicine products. As of 2019, its three products (RCH-01, RCS-01, RCT-01) were in the development phase and its dermal injector device (RCI-02) is under pre-commercialization production and testing phase.

The application of nanotechnology has played a critical role in the process of tissue engineering. Treating neurological diseases is a significant challenge as early diagnosis and treatment initiation is crucial. However, the advent of new 3D designed nanofibers has proved to be a ready alternative to aid the regeneration of damaged neurons. Such advances have propelled the growth of tissue engineering products.

Further key findings from the report suggest:

Cardiology and vascular application is one of the fastest-growing segments owing to an increasing incidence rate of heart failures worldwide

Since the past 20 years, cardiac cell therapy or cardiomyoplasty has been an important focal point of the majority of the studies aimed at heart disease management through regeneration

A rise in the number of children with congenital malformations such as single ventricle anomalies has led to the growing demand for heart transplantation

Tissue-engineered organs help address challenges related to the lack of suitable donor organ and potential side effects related to the transplantation, thereby driving the tissue engineering market growth

Orthopedic, musculoskeletal, and spine segment accounted for the major revenue share in 2019 and is anticipated to dominate the market for tissue engineering through 2027

The high share is attributable to frequent damage to musculoskeletal tissues or loss of tissue in disease or injury with limited repair probability

In addition, a rise in geriatric population, increasing sports-related injuries, and musculoskeletal disorders is also responsible for a high share of orthopedic, musculoskeletal, and spine segment

The lucrative opportunities proposed by emerging economies have drawn the attention of global leaders for investing in the Asia Pacific region. This is attributable to the fastest growth of the market for tissue engineering in the Asia Pacific region throughout the forecast period

Medtronic plc; Zimmer Biomet Holdings, Inc; Allergan plc; Athersys, Inc; ACell, Inc.; Stryker Corporation; Integra LifeSciences Corporation; and Baxter International, Inc. are the key players operating in the market for tissue engineering

These participants are engaged in strategic alliances, deals, and development of novel products to sustain their market share.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
    • 1.1.3 Secondary sources:
  • 1.2 Third party perspective:
    • 1.2.1 Primary research:
  • 1.3 Sample size for the study on Tissue Engineering Market:
    • 1.3.1 Primary Sources
    • 1.3.2 Manufacturers -
    • 1.3.3 Secondary Sources
  • 1.4 Information or Data Analysis
  • 1.5 Market Formulation & Validation
  • 1.6 Objectives
    • 1.6.1 Objective 1
    • 1.6.2 Objective 2

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights
  • 2.4 Market Snapshot, 2019, (USD Million)

Chapter 3 Tissue Engineering Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Related/ancillary market outlook
      • 3.1.2.1 Stem cell market
      • 3.1.2.2 3D cell culture market
  • 3.2 Market Segmentation and Scope
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Advancements in stem cell technology & tissue engineering
      • 3.3.1.1.1 Nanotechnology potential
      • 3.3.1.1.2 Technological advancements in biological implants
      • 3.3.1.1.3 Introduction of novel platforms and technologies
      • 3.3.1.2 Rise in number of clinical studies for regenerative medicine and tissue engineering
      • 3.3.1.3 Increasing tissue engineering research funding
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 High cost of product development
      • 3.3.2.2 Ethical concerns related to stem cell research & tissue engineered product
      • 3.3.2.3 Clinical issues pertaining to development & implementation of stem cell therapies
      • 3.3.2.3.1 Manufacturing issues
      • 3.3.2.3.2 Genetic instability
      • 3.3.2.3.3 Condition of stem cell culture
      • 3.3.2.3.4 Stem cell distribution after transplant
      • 3.3.2.3.5 Immunological rejection
      • 3.3.2.3.6 Challenges associated with allogenic mode of transplantation
  • 3.4 Penetration & Growth Prospects Mapping, by Application, 2019
  • 3.5 Tissue Engineering Market - PESTEL Analysis
  • 3.6 Industry Analysis - Porter's
  • 3.7 Major Deals & Strategic Alliances Analysis
    • 3.7.1 Collaboration & agreement
    • 3.7.2 Joint venture

Chapter 4 Tissue Engineering Market: Application Estimates & Trend Analysis

  • 4.1 Tissue Engineering Market: Application Movement Analysis
  • 4.2 Cord Blood & Cell Banking
    • 4.2.1 Cord Blood & Cell Banking Market, 2016 - 2027 (USD Million)
  • 4.3 Cancer
    • 4.3.1 Cancer Market, 2016 - 2027 (USD Million)
  • 4.4 Gastrointestinal Disorders (GI) and Gynecology
    • 4.4.1 GI & Gynecology Market, 2016 - 2027 (USD Million)
  • 4.5 Dental
    • 4.5.1 Dental Market, 2016 - 2027 (USD Million)
  • 4.6 Skin & Integumentary
    • 4.6.1 Skin & Integumentary Market, 2016 - 2027 (USD Million)
  • 4.7 Urology
    • 4.7.1 Urology Market, 2016 - 2027 (USD Million)
  • 4.8 Orthopedics, Musculoskeletal, & Spine
    • 4.8.1 Orthopedics, Musculoskeletal, & Spine Market, 2016 - 2027 (USD Million)
  • 4.9 Neurology
    • 4.9.1 Neurology Market, 2016 - 2027 (USD Million)
  • 4.10 Cardiology & Vascular
    • 4.10.1 Cardiology & Vascular Market, 2016 - 2027 (USD Million)
  • 4.11 Others
    • 4.11.1 Tissue Engineering Market for Other Applications, 2016 - 2027 (USD Million)

Chapter 5 Tissue Engineering Market: Regional Estimates & Trend Analysis, by Application

  • 5.1 Tissue Engineering Market Share by Region, 2019 & 2027
  • 5.2 North America
    • 5.2.1 North America Tissue Engineering Market, 2016 - 2027 (USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada tissue engineering market, by application, 2016 - 2027 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Tissue Engineering Market, by application, 2016 - 2027 (USD Million)
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France tissue engineering market, by application, 2016 - 2027 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Tissue Engineering Market, 2016 - 2027 (USD Million)
    • 5.4.2 Japan
      • 5.4.2.1 Japan tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 China tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.4.4 India
      • 5.4.4.1 India tissue engineering market, by application, 2016 - 2027 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Tissue Engineering Market, 2016 - 2027 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Tissue engineering market, by application, 2016 - 2027 (USD Million)
    • 5.5.3 Mexico
      • 5.5.3.1 Mexico tissue engineering market, by application, 2016 - 2027 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA Tissue Engineering Market, 2016 - 2027 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa tissue engineering market, by application, 2016 - 2027 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Company Categorization
  • 6.2 Tissue Engineering Market Position Analysis (Based on Products, Market Presence, Service Portfolio, Regional Presence)
  • 6.3 List of key players (public and private) operating in the tissue engineering market
  • 6.4 Strategy Framework
  • 6.5 Company Profiles
    • 6.5.1 Medtronic plc
      • 6.5.1.1 Company overview
      • 6.5.1.2 Financial performance
      • 6.5.1.3 Product benchmarking
      • 6.5.1.4 Strategic initiatives
    • 6.5.2 Zimmer Biomet Holdings, Inc.
      • 6.5.2.1 Company overview
      • 6.5.2.2 Financial performance
      • 6.5.2.3 Product benchmarking
      • 6.5.2.4 Strategic initiatives
    • 6.5.3 Allergan plc
      • 6.5.3.1 Acelity L.P. Inc. (LifeCell)
      • 6.5.3.2 Company overview
      • 6.5.3.3 Financial performance
      • 6.5.3.3.1 Financial performance: Acility
      • 6.5.3.4 Product benchmarking
      • 6.5.3.5 Strategic initiatives
    • 6.5.4 ACell, Inc.
      • 6.5.4.1 Company overview
      • 6.5.4.2 Product benchmarking
      • 6.5.4.3 Strategic initiatives
    • 6.5.5 Athersys, Inc.
      • 6.5.5.1 Company overview
      • 6.5.5.2 Financial performance
      • 6.5.5.3 Product benchmarking
      • 6.5.5.4 Strategic initiatives
    • 6.5.6 Organogenesis Holdings Inc.
      • 6.5.6.1 Company overview
      • 6.5.6.2 Financial performance
      • 6.5.6.3 Product Benchmarking
      • 6.5.6.4 Strategic initiatives
    • 6.5.7 Stryker Corporation
      • 6.5.7.1 Company overview
      • 6.5.7.2 Financial performance
      • 6.5.7.3 Product benchmarking
      • 6.5.7.4 Strategic initiatives
    • 6.5.8 Tissue Regenix Group plc
      • 6.5.8.1 Company overview
      • 6.5.8.2 Financial performance
      • 6.5.8.3 Product benchmarking
      • 6.5.8.4 Strategic initiatives
    • 6.5.9 RTI Surgical, Inc.
      • 6.5.9.1 Company overview
      • 6.5.9.2 Financial performance
      • 6.5.9.3 Product benchmarking
      • 6.5.9.4 Strategic initiatives
    • 6.5.10 ReproCell, Inc.
      • 6.5.10.1 Company overview
      • 6.5.10.2 Product benchmarking
      • 6.5.10.3 Strategic initiatives
    • 6.5.11 Integra LifeSciences Corporation
      • 6.5.11.1 Company overview
      • 6.5.11.2 Financial performance
      • 6.5.11.3 Product benchmarking
      • 6.5.11.4 Strategic initiatives
    • 6.5.12 Baxter International, Inc.
      • 6.5.12.1 Company overview
      • 6.5.12.1.1 Synovis Micro Companies Alliance, Inc.
      • 6.5.12.2 Financial performance
      • 6.5.12.3 Product benchmarking